Tuesday, August 13, 2013

Fall Lupus Walk

 Fall Walk Season is here. Join a Lupus Walk Near You Today!

Enter Coupon Code "Walk" and 10% of your order will go to your walk team!  Be Sure to enter URL in special instructions.
September:Seattle, WA~Nashville, TN~Pittsburgh, PA~Cheektowaga, NY~Pierce, WA~Fayetteville, NC~Lubbock, TX~Jackson, MI~West Haven, CT~Atlanta, GA~Baltimore, MD~Des Moines, IA~Los Angeles, CA~Louisville, KY~Miami, FL~Cleveland, OH~Chicago, IL~Detroit, MI
October:Dallas, TX~Leominster, MA~Cranford, NJ~Richmond, VA~Indianapolis, IN~San Fransisco, CA~Washington D.C.~Chicago, IL~New York, NY~East Meadow, NY~Boston, MA~Philadelphia, PA~San Fransisco, CA
November:Kansas City, MO~Los Angeles, CA
Get details for all of these events here:Lupus Events Calendar

Sunday, July 28, 2013

UCB Announces New Results From Phase 2b Open-Label Extension Study Evaluating The Long-Term Effects Of Epratuzumab In SLE

UCB have announced new data from an open-label extension (SL0008) of the EMBLEM™ phase 2b study evaluating the long-term effects of epratuzumab treatment in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). more...

Wednesday, February 20, 2013

Link Between Uranium Exposure And Increased Lupus Rate

People living near a former uranium ore processing facility in Ohio are experiencing a higher than average rate of lupus, according a new study conducted by scientists at the University of Cincinnati and Cincinnati Children's Hospital Medical Center. more...

Tuesday, January 29, 2013

New hope for lupus patients

A clinical trial with 149 patients suffering from the very disabling autoimmune disease systemic lupus erythematosus, has shown the effectiveness of a synthetic peptide developed by a team of researchers led by CNRS biologist Slyviane Muller at the Institut de Biologie Moleculaire (IBMC) in Strasbourg, France. The peptide, known as P140/LupuzorTM, is well tolerated by patients and leads to regression of the disease. Under the CNRS patent, ImmuPharma-France, which funded the trial, has an exclusive license to use the peptide. Now the final phase of clinical tests should soon confirm these results and contribute to the development of a drug without the side effects of existing treatments, which use cortico-steroids and immunosuppressants. These results are published online in the Annals of the Rheumatic Diseases. more...

Wednesday, December 5, 2012

S.L.E. Lupus Foundation “Turns Lupus Research Upside Down” at Gala 2012

More than 700 members of New York City’s philanthropic, government, business and health care communities joined forces tonight as the S.L.E. Lupus Foundation hosted its Gala 2012 to Turn Lupus Research Upside Down. Held at The American Museum of Natural History, the world’s largest gathering for lupus was hosted by Willie Geist, new co-host of NBC’s Today Show and MSNBC’s Morning Joe. The night raised $2.5 million to turn the tables on lupus with novel innovative research that is producing the pivotal discoveries to improve treatments and uncovering the root causes of lupus that can lead to a cure. more...

Tuesday, November 20, 2012

The Impact Of Rheumatoid Arthritis And Lupus On Joint Replacement Surgery Outcomes

Two new studies by researchers at Hospital for Special Surgery have overturned common beliefs about joint replacement in patients with lupus and rheumatoid arthritis (RA).In one study, researchers demonstrated that RA patients who undergo a knee replacement can expect outcomes that are similar to individuals undergoing the operation for osteoarthritis. more...

Saturday, November 17, 2012

Alliance For Lupus Research And Pfizer’s Centers For Therapeutic Innovation Announce Novel Research Collaboration With Leading Academic Medical Centers

Alliance for Lupus Research (ALR) and Pfizer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus. As part of this first-of-its-kind collaboration in lupus, ALR and CTI will co-fund novel translational research projects driven by leading academic medical centers within the CTI network. more...